Das 3.000-Dollar-Minischwein treibt Europas Drogenpipeline an

*Sara Sjolin for Bloomberg News*

Jens Ellegaard’s pig farm is not like others nestled among the rapeseed and wheat fields of eastern Denmark. There’s no livestock smell, muddy yards or clattering machinery. Breeding units are divided into tightly managed zones where staff follow strict hygiene protocols, water is treated with ultraviolet light, and temperature is regulated by a geothermal system that circulates air through 30 kilometers (19 miles) of underground piping.

The site, Ellegaard Gottingen Minipigs A/S, is more of a biosecurity facility. Its pigs are smaller than standard farm pigs, with some varieties genetically modified to mimic human immune responses and organ function. The animals contributed to the development of Novo Nordisk A/S’s blockbuster diabetes and obesity treatments, Ozempic and Wegovy. And they’re being used by other major pharmaceutical companies to find therapies for illnesses like whooping cough, diseases such as Huntington’s and Parkinson’s, and certain types of cancer.

Easily bred in Europe and relatively inexpensive, selling for about $2,500-$3,000 each, the pigs are quietly emerging as a key part of the European Union’s drive to create a more resilient, competitive biotech sector — one able to withstand the kind of shocks that upended global trade during the coronavirus pandemic and deepened after Donald Trump returned to the White House.

[Read the full dispatch here.](https://www.bloomberg.com/news/articles/2026-02-27/europe-turns-to-minipigs-to-replace-monkeys-in-drug-testing?accessToken=eyJhbGciOiJIUzI1NiIsInR5cCI6IkpXVCJ9.eyJzb3VyY2UiOiJTdWJzY3JpYmVyR2lmdGVkQXJ0aWNsZSIsImlhdCI6MTc3MjM2NzQzOCwiZXhwIjoxNzcyOTcyMjM4LCJhcnRpY2xlSWQiOiJUQjNQWkhLSUpIOUYwMCIsImJjb25uZWN0SWQiOiJEMzU0MUJFQjhBQUY0QkUwQkFBOUQzNkI3QjlCRjI4OCJ9.tOy3WYNgJPwwbulYpZ27vbHccip41uCD7OYrZlSHpQY)